Healthcare
Live Price
Offline$0.8368
+0.00% today
1Y Change
-26.32%
Window
Jun 30, 2025 → Jun 19, 2026
Coverage: 250 bars · Jun 30, 2025 → Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) is a Healthcare stock with a market cap of $16.17B and listed on OTC. The stock last traded around $0.84 and down 26.3% across the available one-year price window (Jun 30, 2025 → Jun 19, 2026). Baseline metrics include revenue growth of +9.0%, EPS growth of -94.0%, a dividend yield of 4.8%. What stands out right now is revenue +9.0%, EPS -94.0%, free cash flow -51.7% with operating margin 21.2% and ROIC 14.4%. The dividend matters to the case here, with a current yield around 4.8%. Valuation is more restrained than many high-expectation growth names at P/E 9.7 and price/sales 0.9. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines GNMLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
GNMLF is 47.18 pts behind over the shared 1Y window.
GNMLF had 19.07 pts deeper max drawdown than SPY.
GNMLF beat SPY in 0 of 2 calendar years shown and trailed in 2.
GNMLF
-26.32%
Normalized return
SPY
+20.86%
S&P 500
Excess Return
-47.18 pts
Relative to SPY
GNMLF Max Drawdown
-28.21%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for GNMLF and SPY.
| Year | GNMLF | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -20.75% | +6.71% | -27.46 pts | SPY |
| 2025 | -7.02% | +11.19% | -18.21 pts | SPY |
Unable to load analyst forecasts.
Timed out loading forecasts for GNMLF
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.